Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles
Certain insulins are comparable; Public Citizen criticizes Cures provision on orphan-drug exclusivity; the FDA approves Kanuma
AstraZeneca plans to incorporate a mobile app that gathers information about side effects in three clinical trials studying an experimental combination therapy for ovarian cancer.
Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug
GSK partners with other drugmakers to bolster pipeline; Pfizer makes deal in South Africa for Prevnar 13; the FDA issues guidance on HIV biologic development
Therapy and low-dose drugs found to aid schizophrenia patients more than just antipsychotics; Clinton calls for investigations into drug price increases; Bayer issues RFP for AOR for consumer care brands
The NIH plans to fund fewer but more meaningful studies; the FDA asks for more data about AstraZeneca diabetes drug; payers continue to deny coverage for new hep.-C treatments
Lilly stops trial for experimental heart drug; Turing misses deadline to respond to lawmakers about price increase of Daraprim; the FDA expands indication for Opdivo
Califf reportedly removes name from research questioning FDA oversight of clinical trials; Express Scripts to cover both PCSK9 inhibitors; trial for experimental cancer drug halted after patient death
A GSK manager said that bringing digital devices to clinical trials could lower the cost of bringing medicines to patients.
By equipping patients with biosensors, wearable devices and mobile apps, clinical R&D teams have the opportunity to gain unprecedented insight about the patient experience.
PhRMA hires Ubl as CEO; two drugs report superior results in kidney-cancer trials compared to the standard of care; Novo Nordisk's shares rise on Tresiba approval
Craig Rothenberg joined Turing as its first comms chief less than two months ago.
As the value proposition of real-world data to drugmakers becomes increasingly attractive, services companies are partnering to capitalize on the opportunity.
Longtime ICC leader Viviano moves to the client side to help the start-up build its marketing team and become a commercial contender.
Sprout's controversial sexual-desire drug receives FDA approval; prescription-drug coverage impacts cash sales at Walmart; Mylan warned about manufacturing violations
State attorneys general accused the drugmaker of violating state consumer protection laws.
Biogen to map ALS genes with Ice Bucket Challenge funds; Merck seeks first-line indication for Keytruda; lawmaker criticizes FDA approval of OxyContin for children
Purdue Pharma launched a new resource around the abuse-deterrent properties of some of its painkillers.
But don't expect the floodgates to open. Marketers still have to take a legal route to promote such information.
GSK studying Breo Ellipta in lung-cancer patients; researchers develop strains of yeast for painkillers in a lab; Wolters Kluwer acquires CME provider
ViiV Healthcare, a joint venture by Pfizer and GlaxoSmithKline, has appointed Porter Novelli to manage its corporate comms account, PRWeek understands.
Know a very special person or group making extraordinary contributions to public health? We want to hear from you.
While social media can be a tool for pharma to help educate the public, it has also become a forum for the public to express their views about pharma, and it's not always flattering, as evidenced by the recent antivaccine movement.
The media company said orphan drugs and specialty medicines, like PCSK9 inhibitors, will drive the company's business going forward.
J&J turns to digital marketing in China; GSK closes North Carolina facility; Kim Kardashian West's promotion of Diclegis increased online conversations about the brand
The company acquired Tea Leaves Health for $30 million to diversify its business.
"Me-too" drugs may help lower costs; start-ups send doctors to your home; the FDA is likely to appeal the Amarin ruling
By breaking down traditional organizational silos to bring together the chief medical officer and the chief marketing officer, companies can unite the forces of clinical best practices with direct-to-consumer response marketing.
The decision, a setback for the FDA, allows the drugmaker to move forward with plans to legally promote some off-label information.
Test your knowledge in this week's edition of the MM&M Weekly News Quiz.
CVS excludes 31 drugs including Viagra from its 2016 formulary; Sanofi partners with Evotec on stem-cell treatment development; primary-care physicians may hesitate to prescribe Truvada for PrEP
Allergan executives attributed strong sales of branded products to recent investments in direct-to-consumer advertising.
AstraZeneca signs two immuno-oncology collaboration deals; UK cost watchdog goes after Pfizer over epilepsy medication price tag; Boston Globe reports drugmakers are funneling more money through CME programs
Findings of a new report suggest ways pharma should rethink its commercial and R&D decisions in light of improved survival rates associated with some cancers.
The drugmaker, which sells prostate-cancer treatment Xtandi, wants social-media users to help spread the word about the disease
The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information
Recent deals show these companies are expanding their EHR networks, and the number of physicians who gain access to copay coupons, vouchers and other forms of assistance.
Eylea's robust second quarter of sales can be attributed in part to its ability to erase market share of competitors.
Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014
The PBM said AstraZeneca's diabetes medications Onglyza and Kombiglyze XR will not be covered next year.
From evolving healthcare laws to social engagement, litigation crises to media relations, McKesson's PR chief is hands-on in efforts to enhance the brand's image.
Shire buys Foresight Biotherapeutics for $300 million; Novartis sold off three investigational drugs into Mereo BioPharma; new blood thinners linked to 8,000 deaths since 2010
Test your knowledge in this week's edition of the MM&M Weekly News Quiz.
Lawsuit alleges CVS overbilled insurance companies for generic drugs; a Merck vaccine is shown to be effective in treating Ebola; the FDA approves Bayer's rosacea treatment
The New York-based agency took a majority stake in the full-service healthcare agency.
The "Surprise, it's insulin" campaign follows criticism of the lower-than-expected sales of the inhaled insulin since its launch in February.
Copaxone sales rise despite generic competition; Valeant to defend tax strategy; Bristol-Myers Squibb to test Opdivo with mogamulizumab in the US
More patients are seeking treatments with even fewer side effects and shorter durations.
Turing Pharmaceuticals hired Craig Rothenberg, who spent 20 years with Johnson & Johnson, to lead the recently founded drugmaker's communications operations.
Drug spending projected to grow at 6% clip through 2024, spurred in part by pricey new medications; FDA approves new obesity device; Sanofi diabetes combo drug is better at reducing blood glucose than Lantus.
View on a quarter-by-quarter basis the competitive market for four new hepatitis-C treatments and track how Gilead Sciences' Harvoni became the market leader within months of receiving approval from the FDA.
The immuno-oncology drug is competing with Bristol-Myers Squibb's Opdivo.
The drugmaker told investors that the actual-use trial failed to meet the primary objectives.
Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe
The integrated agency's pharmaceutical business now brings in half its billings.
Teva will acquire Allergan's generic drug business; AstraZeneca sells rights to cancer drug to Sanofi; the FDA approves two drugs heading into the weekend
Today's cancer therapies have an unlikely champion in their corner: the immune system. Scientists are training the natural disease defender to KO cancer for good—and pharma companies are drooling over the flashy premium prices and commercial success of marketed immunotherapies, which have ignited vigorous pipeline work. Rebecca Mayer Knutsen surveys the $32-billion US cancer segment
The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.
Test your knowledge in the inaugural edition of the MM&M Weekly News Quiz.
UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth
Bristol-Myers Squibb reported a dip in US sales for the second quarter of 2015 but noted higher uptake for its immunoncology drug, Opdivo.
Oncologists criticize cancer drug prices; Mylan exercises option to fend off Teva takeover; Valeant buys IBS diagnostic in latest acquisition
The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.
A next-generation cardiovascular drug is expected to be approved this week, but concerns abound about who will take it—and how much it will cost.
Experimental Alzheimer's disease drugs produce mixed results; court rules in favor of Novartis in Zarxio case; Horizon Pharma increases its bid for Depomed
The modern healthcare landscape is complicated, and the terrain is even more gnarled for life sciences companies trying to bring new products to market.
The new campaign seeks to connect with millennial women.
Physicians criticize pricing of Orkambi, Vertex's new cystic-fibrosis drug; the EU approves Amgen's PCSK9 inhibitor Repatha; PhRMA boosts lobbying spending in the second quarter
New rules will require manufacturers to report some indirect payments made to physicians for CME activities.
The agency plans to research extrinsic factors that influence the way a patient perceives a drug.
Robert Ingram sounds off on drug transparency laws in WSJ op-ed; patients with certain forms of leukemia went into complete remission after taking Amgen's cancer drug; Eli Lilly's future in Alzheimer's disease pinned to new data surfacing this week
Gilead will limit financial assistance to patients to pressure payers; Biogen reports another PML case related to Tecfidera; Valeant buys Egyptian drugmaker
The National Organization for Rare Disorders and the University of Maryland will develop a training program to help caregivers and patients participate in research.
The pharma business needs to take engagement far more seriously than it has in the past. At the same time, there are signs that the industry is finally acting with more urgency and even transparency.
The backlash to expensive specialty medications has forced the drug industry to partner up to prove the benefits of their medicines in the real world, according to a PwC analysis.
The restructuring is expected to simplify the drugmaker's organization.
Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands
Johnson & Johnson CEO Alex Gorsky said physicians are unlikely to switch the majority of patients to a biosimilar version of Remicade.
Vesey Street Capital Partners acquired Atlanta-based CME provider Imedex.
The FDA approves AstraZeneca's Iressa as a first-line lung-cancer therapy; Mylan and Dr. Reddy's launch generic versions of dementia treatment Namenda; health insurer consolidation may lead to pressure on drug prices
PhRMA and the Epilepsy Foundation said 50-million Americans are affected by disorders such as Alzheimer's disease and multiple sclerosis.
Harvoni is now prescribed more than Sovaldi; healthcare group says new hepatitis-C drugs are cost-effective; Roche antibody shrank tumors in certain bladder-cancer patients
21st Century Cures legislation passes the House; Novartis's heart-failure drug may launch with "beyond the pill" services; Purdue and GSK are working on using Apple's ResearchKit; the FDA issues warning letter on co-pay card
The legislation would allow drugmakers to share information about their products beyond what is included on the FDA-approved label.
Pregnant women taking Prozac or Paxil have higher risks of birth defects; study finds J&J's experimental psoriasis drug works better than Humira; AstraZeneca divests global rights to Entocort
An FDA advisory panel will discuss the fate of Lilly's investigational lung-cancer antibody, necitumumab, which improved overall survival incrementally but also had one late-stage trial halted due to an "imbalanced number of deaths" attributed to blood clots.
The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.
CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen
An analysis by a state insurance trade group forecast that paying for new HCV treatments could cost taxpayers billions of dollars.
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
The Boston-based biotech saw its novel cystic-fibrosis drug, Orkambi, receive approval, but it could face an uphill climb in convincing payers to pay for it.
Vertex's cystic-fibrosis drug scores approval; Bloomberg Business analysis finds competitive product categories attract the most marketing dollars; Allergan makes a deal with developmental medical-device company
Biogen pursues orphan eye-disease treatments; Novo Nordisk will stop selling Tresiba in Germany over price controversy; the switch to Prevnar 13 is expected to lower costs
The social networking site for doctors also plans to expand to its first Spanish-speaking country next month.
The health insurance industry's trade association, along with other organizations, sent a letter to the FDA arguing that different names could lead to prescriber confusion and medication errors.
Purdue withdraws plans to participate in FDA meeting on painkillers; Allscripts takes 10% stake in NantHealth in advance of IPO; union advocates to end pharma support for CME
Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol
The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.
A new Novartis drug shows promise; Samsung Group is poised to move on its next major growth sector; Valeant Pharmaceuticals is on the hunt again
- Five things for pharma marketers to know: Friday, February 5, 2016
- Why Gathering Health Economic Data for Cancer Drugs is Now Essential
- Ascension Health ups Ragone to chief marcomms officer
- House Oversight committee upbraids Turing, Valeant execs
- Burcin departs Havas network for Klick Health in senior-staffing push